ProQR Therapeutics (PRQR) EBIAT (2021 - 2025)
Historic EBIAT for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$12.9 million.
- ProQR Therapeutics' EBIAT fell 4449.79% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.2 million, marking a year-over-year decrease of 8137.66%. This contributed to the annual value of -$30.0 million for FY2024, which is 15.84% down from last year.
- Per ProQR Therapeutics' latest filing, its EBIAT stood at -$12.9 million for Q3 2025, which was down 4449.79% from -$13.8 million recorded in Q2 2025.
- In the past 5 years, ProQR Therapeutics' EBIAT registered a high of $20.9 million during Q4 2021, and its lowest value of -$23.5 million during Q3 2022.
- Its 5-year average for EBIAT is -$8.7 million, with a median of -$9.9 million in 2024.
- Its EBIAT has fluctuated over the past 5 years, first soared by 7488.95% in 2023, then tumbled by 37555.1% in 2025.
- Quarter analysis of 5 years shows ProQR Therapeutics' EBIAT stood at $20.9 million in 2021, then tumbled by 165.03% to -$13.6 million in 2022, then surged by 56.52% to -$5.9 million in 2023, then tumbled by 68.55% to -$9.9 million in 2024, then decreased by 29.4% to -$12.9 million in 2025.
- Its EBIAT stands at -$12.9 million for Q3 2025, versus -$13.8 million for Q2 2025 and -$10.6 million for Q1 2025.